FDA advisers unanimously back J&J hepatitis C drug

By: AP Email
By: AP Email

SILVER SPRING, Md. (AP) -- An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.

All 19 members of a panel of Food and Drug Administration advisers voted unanimously in favor of approving J&J's simeprevir, a daily pill designed to eliminate the most common form of hepatitis C.

The FDA is not required to follow the group's recommendation, though it often does. A decision on the drug is expected next month.

More than 3 million people in the U.S. have hepatitis C, a blood-borne disease that causes liver damage and is blamed for 15,000 deaths a year. J&J is one of a half-dozen companies working to develop more effective treatments for the virus.


You must be logged in to post comments.

Username:
Password (case sensitive):
Remember Me:
WEAU 13 NEWS 1907 S. Hastings Way Eau Claire, WI 54701 By Phone: Main Number (715) 835-1313 and (715) 832-3474. Tip Line (715) 839-WEAU - (715) 839-9328 Sports Line (715) 852-1537
Copyright © 2002-2016 - Designed by Gray Digital Media - Powered by Clickability 229156861 - weau.com/a?a=229156861
Gray Television, Inc.